166 related articles for article (PubMed ID: 31440502)
1. Synthesis of Dextran-Phenoxodiol and Evaluation of Its Physical Stability and Biological Activity.
Yee EMH; Cirillo G; Brandl MB; Black DS; Vittorio O; Kumar N
Front Bioeng Biotechnol; 2019; 7():183. PubMed ID: 31440502
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of isoflavene-thiosemicarbazone hybrids and evaluation of their anti-tumor activity.
Yee EMH; Brandl MB; Black DS; Vittorio O; Kumar N
Bioorg Med Chem Lett; 2017 Jun; 27(11):2454-2458. PubMed ID: 28408225
[TBL] [Abstract][Full Text] [Related]
3. Preparation, characterization and in vitro biological evaluation of (1:2) phenoxodiol-β-cyclodextrin complex.
Yee EM; Hook JM; Bhadbhade MM; Vittorio O; Kuchel RP; Brandl MB; Tilley RD; Black DS; Kumar N
Carbohydr Polym; 2017 Jun; 165():444-454. PubMed ID: 28363571
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, biological evaluation and structure-activity relationship studies of isoflavene based Mannich bases with potent anti-cancer activity.
Chen Y; Cass SL; Kutty SK; Yee EM; Chan DS; Gardner CR; Vittorio O; Pasquier E; Black DS; Kumar N
Bioorg Med Chem Lett; 2015 Nov; 25(22):5377-83. PubMed ID: 26432036
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of novel isoflavene-propranolol hybrids as anti-tumor agents.
Yee EM; Pasquier E; Iskander G; Wood K; Black DS; Kumar N
Bioorg Med Chem; 2013 Apr; 21(7):1652-60. PubMed ID: 23462711
[TBL] [Abstract][Full Text] [Related]
6. Dextran-catechin conjugate: a potential treatment against the pancreatic ductal adenocarcinoma.
Vittorio O; Cirillo G; Iemma F; Di Turi G; Jacchetti E; Curcio M; Barbuti S; Funel N; Parisi OI; Puoci F; Picci N
Pharm Res; 2012 Sep; 29(9):2601-14. PubMed ID: 22622510
[TBL] [Abstract][Full Text] [Related]
7. Glycosylation of Semi-Synthetic Isoflavene Phenoxodiol with a Recombinant Glycosyltransferase from
Seo M; Seol Y; Park JW
J Microbiol Biotechnol; 2022 May; 32(5):657-662. PubMed ID: 35131959
[TBL] [Abstract][Full Text] [Related]
8. The anti-cancer drug, phenoxodiol, kills primary myeloid and lymphoid leukemic blasts and rapidly proliferating T cells.
Herst PM; Davis JE; Neeson P; Berridge MV; Ritchie DS
Haematologica; 2009 Jul; 94(7):928-34. PubMed ID: 19535345
[TBL] [Abstract][Full Text] [Related]
9. Phenoxodiol protects against Cisplatin induced neurite toxicity in a PC-12 cell model.
Klein R; Brown D; Turnley AM
BMC Neurosci; 2007 Aug; 8():61. PubMed ID: 17672914
[TBL] [Abstract][Full Text] [Related]
10. ECTO-NOX target for the anticancer isoflavene phenoxodiol.
Morré DJ; Chueh PJ; Yagiz K; Balicki A; Kim C; Morré DM
Oncol Res; 2007; 16(7):299-312. PubMed ID: 17518268
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, characterization, and cytotoxicity evaluation of dextran-myristoyl-ECGKRK peptide conjugate.
El-Sayed NS; Sajid MI; Parang K; Tiwari RK
Int J Biol Macromol; 2021 Nov; 191():1204-1211. PubMed ID: 34597704
[TBL] [Abstract][Full Text] [Related]
12. Phenoxodiol-Topotecan co-administration exhibit significant anti-tumor activity without major adverse side effects.
Alvero AB; Brown D; Montagna M; Matthews M; Mor G
Cancer Biol Ther; 2007 Apr; 6(4):612-7. PubMed ID: 17457041
[TBL] [Abstract][Full Text] [Related]
13. Enzymatic synthesis of novel unnatural phenoxodiol glycosides with a glycosyl donor flexible glycosyltransferase MeUGT1.
Lee NJ; Kwon Y; Kang W; Seo M; Seol Y; Park JW
Enzyme Microb Technol; 2022 Nov; 161():110113. PubMed ID: 35998478
[TBL] [Abstract][Full Text] [Related]
14. Water Soluble Antioxidant Dextran-Quercetin Conjugate with Potential Anticancer Properties.
Oliver S; Yee E; Kavallaris M; Vittorio O; Boyer C
Macromol Biosci; 2018 Apr; 18(4):e1700239. PubMed ID: 29411934
[TBL] [Abstract][Full Text] [Related]
15. Phenoxodiol inhibits growth of metastatic prostate cancer cells.
Aguero MF; Venero M; Brown DM; Smulson ME; Espinoza LA
Prostate; 2010 Aug; 70(11):1211-21. PubMed ID: 20564423
[TBL] [Abstract][Full Text] [Related]
16. Phenoxodiol enhances the antitumor activity of gemcitabine in gallbladder cancer through suppressing Akt/mTOR pathway.
Li Y; Huang X; Huang Z; Feng J
Cell Biochem Biophys; 2014 Nov; 70(2):1337-42. PubMed ID: 24902539
[TBL] [Abstract][Full Text] [Related]
17. The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells.
Herst PM; Petersen T; Jerram P; Baty J; Berridge MV
Biochem Pharmacol; 2007 Dec; 74(11):1587-95. PubMed ID: 17904534
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells.
McPherson RA; Galettis PT; de Souza PL
Br J Cancer; 2009 Feb; 100(4):649-55. PubMed ID: 19209173
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Therapeutic Potential of Phenoxodiol, a Novel Isoflavone Analog, in Renal Cancer Cells.
Isono M; Sato A; Asano T; Okubo K; Asano T
Anticancer Res; 2018 Oct; 38(10):5709-5716. PubMed ID: 30275191
[TBL] [Abstract][Full Text] [Related]
20. Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1.
Aguero MF; Facchinetti MM; Sheleg Z; Senderowicz AM
Cancer Res; 2005 Apr; 65(8):3364-73. PubMed ID: 15833870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
